Skip to main content

Table 4 The structures of PROTAC molecules targeting cancer immune evasion or inflammation. (red: POI ligand; yellow: E3 ligand)

From: Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Target

PROTAC

PROTAC structure

Cancer

Ref

Target

PROTAC

PROTAC structure

Cancer

Ref

PD-L1

P22

NSCLC TNBC, M

[215]

FKBP12

dFKBP-1

AML

[12]

BTK

DD-04-015

DLBCL

[161]

FKBP12

dTAG-13

AML

[225]

BTK

P13I

BL, DLBCL, MCL

[216]

FKBP12

RC32

T-ALL, BL, PC, BC, CC

[226]

BTK

RC-3

BL, MCL, CML

[217]

FKBP12

KB02-SLF

/

[97]

BTK

RC-1

AML, MCL

[227]

HPK1

SS44

BL, MM,

CML, et al

[220]

BTK

BC5P

AML

[219]

IDO1

degrader 2c

CC

[221]

BTK

DD-03-171

MCL, DLBCL

[218]

IKZF1/3

DD-03-171

MCL, DLBCL

[218]

BTK

compound 10

BL, AML

[228]

IRAK4

degrader-5

DLBCL

[229]

BTK

PROTAC 7

BL, CML

[118]

ITK

TL12-186

AML, T-ALL

[161]

STAT3

SD-36

AML, ALCL

[57]

JAK

JP-6

AML

[222]

CD147

compound 6a

M

[230]

Lin28

ORN3P1

CML

[18]

PDE4

SNIPER(PDE4)-9

FS

[89]

PRC2

PROTAC 1

DLCBL

[231]

PDEδ

compound 17f

CRC

[232]

PRMT5

MS4322

BC

[233]

PDEδ

PROTAC 3

T-ALL, PaC, CC

[234]

Rpn13

WL-40

MM

[235]

Pirin

CCT367766

OC

[236]

SHP2

SHP2-D26

EC, AML

[223]

PRC2

UNC6852

CC, DLCBL

[237]

TBK1

PROTAC 3i

NSCLC

[238]